| (Values in U.S. Thousands) | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 |
| Sales | 24,010 | 25,260 | 20,910 | 30,040 | 4,510 |
| Sales Growth | -4.95% | +20.80% | -30.39% | +566.08% | +478.21% |
| Net Income | -29,810 | -19,620 | -24,460 | -18,220 | 4,770 |
| Net Income Growth | -51.94% | +19.79% | -34.25% | -481.97% | +126.05% |
Cardiome Pharma Corp (CRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.